AstraZeneca signs AI drug discovery deal with insitro worth up to $1.86 billion

The pharma giant is betting on insitro's Virtual Human platform to find new targets in fatty liver disease and heart muscle disorders AstraZeneca has signed a drug discovery collaboration with insitro, the AI-driven biotech, in a deal Bloomberg reported is worth up to $1.86 billion. The goal is to find new biological targets for two notoriously stubborn disease areas. One is a liver condition most people have never heard of. The other involves the heart muscle itself. The partnership, announced on October 15, 2026, focuses on metabolic dysfunction-associated steatohepatitis, or MASH. That is the clinical name for an advanced form of fatty liver disease. The second focus is cardiomyopathies, a group of disorders that affect the heart muscle.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to Crypto Briefing.